Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Vivani Medical, Inc.

Get SEC filing alerts via email and in your feed for Vivani Medical, Inc.

VANI VANIW

Vivani Medical, Inc.

About Vivani Medical, Inc.

Vivani Medical, Inc. is a biopharmaceutical company developing proprietary NanoPortal subdermal drug implants for long-acting delivery of medicines targeting chronic diseases like obesity and type 2 diabetes. Its platform aims to improve medication adherence and tolerability through miniaturized, controlled-release implants, primarily using GLP-1 therapeutics. The company focuses on clinical-stage programs, strategic collaborations, and intellectual property to revolutionize chronic disease treatment.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Vivani Medical, Inc.

1
1
Vivani Medical, Inc. Vivani Medical Reports $6.8 Million Net Loss in Q1 2026, Increases R&D Spending

Via official filing (AI summary) | 22 days ago | 0 comments

2
1
Vivani Medical, Inc. Vivani Medical Reports $26.6 Million Net Loss for Fiscal Year 2025

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
Vivani Medical, Inc. Vivani Medical Reports $6.5 Million Net Loss in Q3 2025, Focuses on Product Development

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Vivani Medical, Inc. Vivani Medical Reports $7.1 Million Net Loss in Q2 2025, Sees Increase in Operating Expenses

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Vivani Medical, Inc. Vivani Medical Reports $6.3 Million Net Loss in Q1 2025, Focuses on Biopharmaceutical Initiatives

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Vivani Medical, Inc. Vivani Medical Reports $23.5 Million Net Loss for Fiscal Year 2024, Focuses on Clinical Development

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Vivani Medical, Inc. Vivani Medical Reports Improved Financials, Advances Clinical Programs for GLP-1 Implant Candidates

Via official filing (AI summary) | over 1 year ago | 0 comments